Get the Daily Brief
Latest Biotech News
Palbociclib reverses venetoclax resistance in AML – OHSU combination shows durable activity
Researchers at Oregon Health & Science University reported that combining venetoclax with palbociclib produced stronger and more durable anti‑leukemia activity in AML models than venetoclax alone....
Rare variant weakens MSI2 – lowers clonal hematopoiesis and leukemia risk
A GWAS meta‑analysis of more than 640,000 people identified a rare noncoding variant, rs17834140‑T, that reduces clonal hematopoiesis of indeterminate potential (CHIP) and decreases leukemia risk...
AbbVie buys ex‑China rights to Zelgen's DLL3 engager: $1.1B deal
AbbVie signed a deal to acquire ex‑China rights to Zelgen Biopharmaceuticals' lead oncology candidate alveltamig (ZG‑006), a trispecific T‑cell engager targeting DLL3. Under terms disclosed,...
Transcenta licenses HiCB to EirGenix – push for continuous biomanufacturing
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and hybrid continuous...
St. Jude unveils method to detect base‑editor off‑targets: higher sensitivity
St. Jude Children's Research Hospital released a new method designed to more sensitively detect small off‑target edits caused by base editors used in gene editing. The authors argue the technique...
Venetoclax resistance tackled by breast‑cancer drug palbociclib – OHSU study
Researchers at Oregon Health & Science University report that combining the BCL2 inhibitor venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia...
Inherited variant slows clonal hematopoiesis: Science reports leukemia protection
A GWAS meta‑analysis of more than 640,000 individuals led by Vijay Sankaran's lab identified a rare noncoding variant, rs17834140‑T, that reduces risk of clonal hematopoiesis of indeterminate...
FDA issues third CRL for Outlook's ONS‑5010 – stock dives
Outlook Therapeutics received a third complete response letter from the U.S. FDA for ONS‑5010, its bevacizumab biosimilar formulated for wet age‑related macular degeneration. The company’s stock...
Psithera spins out of Roivant with $47.5M – new immunology small‑molecule shop
Psithera Inc. emerged from Roivant as an independent company with a $47.5 million Series A and new CEO Eric Shaff, repositioning the group to focus on small‑molecule immune and inflammatory...
Engineered co‑signaling receptors sharpen T‑cell precision: study
A team led by Cabezas‑Caballero and colleagues reported engineered co‑signaling receptors that improve T‑cell targeting precision and reduce off‑target cross‑reactivity. The study describes...
Autologous iPSC lung‑on‑a‑chip models early TB events: personalized platform
Researchers from the Francis Crick Institute and AlveoliX reported an autologous alveolus‑on‑a‑chip built entirely from iPSC‑derived cells from a single donor. Published in Science Advances, the...
Engineered IL‑10 targets LDL to cut vascular inflammation – study
A Nature Biomedical Engineering study engineered IL‑10 to target LDL particles and reported targeted delivery reduced vascular inflammation in preclinical atherosclerosis models. The approach...
AbbVie buys ex‑China rights to Zelgen’s DLL3 T‑cell engager – $1.1B pact
AbbVie signed a $1.1 billion deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ lead trispecific T‑cell engager, alveltamig (ZG‑006), targeting DLL3. Under the agreement announced Dec....
Transcenta licenses HiCB platform to EirGenix: CDMO collaboration for continuous biologics
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and integrated hybrid continuous...
Insilico posts big gains after Hong Kong listing – finance report
Insilico Medicine recorded a substantial market gain following its Hong Kong listing, according to a BioCentury finance report. The listing outcome boosted Insilico’s public valuation and...
Psithera exits Roivant, raises $47.5M to pursue immune and inflammatory small molecules
Psithera Inc. spun out from Roivant and closed a $47.5 million Series A financing while appointing Eric Shaff as president and CEO. The Watertown, Mass. company repositioned itself to develop...
Third FDA CRL derails Outlook’s ONS‑5010 – shares plunge
Outlook Therapeutics received a third complete response letter (CRL) from the U.S. Food and Drug Administration for ONS‑5010, its bevacizumab formulation for wet age‑related macular degeneration....
AML resistance tackled... palbociclib plus venetoclax shows durable activity
Researchers at Oregon Health & Science University reported that combining the CDK4/6 inhibitor palbociclib (approved in breast cancer) with venetoclax produced stronger, more durable anti‑leukemia...
AIM platform: single‑strand deaminase enables precise, tunable RNA edits
A new RNA‑editing technology, termed AIM (Adjustable RNA Information Manipulation), uses a single‑strand deaminase to enable controllable, site‑specific RNA editing, according to a Nature...
St. Jude method: better detection of base‑editor off‑targets
Scientists at St. Jude Children’s Research Hospital published a new method to detect small off‑target edits produced by base editors, addressing a major technical and safety challenge in precision...